Overview

Trial of an Injectable Biologic and U0279 as Combination Therapy for Severe Plaque-Type Psoriasis

Status:
Withdrawn
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess the safety and efficacy of an injectable biologic and U0279 as combination therapy compared to that of an injectable biologic alone for severe plaque-type psoriasis.
Phase:
Phase 4
Details
Lead Sponsor:
Stiefel, a GSK Company
Collaborator:
GlaxoSmithKline
Treatments:
Acitretin
Etanercept